QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 deutsche-bank-maintains-hold-on-definitive-healthcare-lowers-price-target-to-7

Deutsche Bank analyst George Hill maintains Definitive Healthcare (NASDAQ:DH) with a Hold and lowers the price target from $...

 barclays-maintains-equal-weight-on-definitive-healthcare-lowers-price-target-to-7

Barclays analyst Saket Kalia maintains Definitive Healthcare (NASDAQ:DH) with a Equal-Weight and lowers the price target fro...

 buy-definitive-healthcare-stock-on-weakness-analyst-says-as-revised-outlook-appears-achievable

Definitive Healthcare reports Q1 adjusted EPS of $0.08, sales at $63.48M, and adjusted EBITDA of $20 million. Q2 revenue guidan...

 canaccord-genuity-maintains-hold-on-definitive-healthcare-lowers-price-target-to-8

Canaccord Genuity analyst David Hynes maintains Definitive Healthcare (NASDAQ:DH) with a Hold and lowers the price target fr...

 stifel-maintains-buy-on-definitive-healthcare-lowers-price-target-to-95

Stifel analyst David Grossman maintains Definitive Healthcare (NASDAQ:DH) with a Buy and lowers the price target from $11 to...

 needham-reiterates-hold-on-definitive-healthcare

Needham analyst Ryan MacDonald reiterates Definitive Healthcare (NASDAQ:DH) with a Hold.

 morgan-stanley-downgrades-definitive-healthcare-to-equal-weight-lowers-price-target-to-9

Morgan Stanley analyst Craig Hettenbach downgrades Definitive Healthcare (NASDAQ:DH) from Overweight to Equal-Weight and low...

 definitive-healthcare-q1-2024-adj-eps-008-inline-sales-63480m-miss-63990m-estimate

Definitive Healthcare (NASDAQ: DH) reported quarterly earnings of $0.08 per share which met the analyst consensus estimate.

 barclays-maintains-equal-weight-on-definitive-healthcare-raises-price-target-to-11

Barclays analyst Saket Kalia maintains Definitive Healthcare (NASDAQ:DH) with a Equal-Weight and raises the price target fro...

 challenging-times-for-definitive-healthcare-analysts-highlight-sluggish-growth-and-recovery-efforts-in-q4-analysis

Definitive Healthcare's Q4 2023 performance, with adjusted EPS at $0.07, sales of $65.93 million, and a 5% Y/Y growth in en...

 canaccord-genuity-maintains-hold-on-definitive-healthcare-raises-price-target-to-10

Canaccord Genuity analyst David Hayes maintains Definitive Healthcare (NASDAQ:DH) with a Hold and raises the price target fr...

 definitive-healthcare-sees-fy24-revenue-263m-269m-vs-27029m-estimate

Full Year 2024:  Revenue is expected to be in the range of $263.0 – $269.0 million, a 5-7% increase from the prior year at the ...

 definitive-health-sees-fy24-revenue-63m-65m-vs-6577m-estimate

Business Outlook Based on information as of February 28, 2024, the Company is issuing the following financial guidance. This gu...

 definitive-healthcare-q4-2023-adj-eps-007-misses-008-estimate-sales-6593m-miss-6602m-estimate

Definitive Healthcare (NASDAQ:DH) reported quarterly earnings of $0.07 per share which missed the analyst consensus estimate of...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION